# A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy

Study · id `cardio:ct-nct06797869` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06797869](<https://clinicaltrials.gov/study/NCT06797869>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06797869

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 142 participants.

## Technical summary

Registry record NCT06797869. Randomized; quadruple masking; primary purpose treatment. Start 2025-01-29 (actual); primary completion 2026-06-26 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 142 participants (enrolled count; ClinicalTrials.gov record NCT06797869, source copy `cardio:ctgov-nct06797869-2026-09-10`, retrieved 2026-10-26)
- Started: 2025-01-29 (actual) (ClinicalTrials.gov record NCT06797869, source copy `cardio:ctgov-nct06797869-2026-09-10`, retrieved 2026-10-26)
- Primary completion: 2026-06-26 (actual) (ClinicalTrials.gov record NCT06797869, source copy `cardio:ctgov-nct06797869-2026-09-10`, retrieved 2026-10-26)
- Completion: 2026-08-05 (actual) (ClinicalTrials.gov record NCT06797869, source copy `cardio:ctgov-nct06797869-2026-09-10`, retrieved 2026-10-26)
- Countries: United States; Canada; Denmark; France; Norway; Spain; United Kingdom (ClinicalTrials.gov record NCT06797869, source copy `cardio:ctgov-nct06797869-2026-09-10`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06797869-2026-09-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
- Condition: Diabetes Mellitus, Type 2
- Condition: Diabetic Peripheral Neuropathy
- Intervention (Drug): CagriSema (Cagrilintide B and Semaglutide I)
- Intervention (Drug): Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

## Provenance

Content hash: ef5fc21945788c9d9ed419832c8dc81688b8f8f7f6fc23d0163918975ecdace1
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
